The 5 most recent market catalysts affecting $MRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 55
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
Monte Rosa Therapeutics (MRTX) announced the presentation of preclinical data for its gout candidate, MRT-8102, at a medical conference. This is a routine update for a biotechnolog…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 75
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics (MRTX) reported Q3 2026 financial results, showcasing a robust cash position of $582.6 million, projected to fund operations into 2029. This strong financia…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 65
Monte Rosa Therapeutics Announces Milestone Achievement for MRT-6160 Clinical Study
Monte Rosa Therapeutics (MRTX) announced the receipt of a $37.5 million milestone payment from Novartis (NVS) following the initiation of a second Phase 2 clinical study for their …
Sep 30, 2026
Corporate Catalyst
Neutral
Impact 75
Monte Rosa Therapeutics To Present Phase 1 Data For MRT-8102 In People With Elevated Cardiovascular Risk On October 1
This headline represents a significant corporate catalyst for Monte Rosa Therapeutics (MRTX). The presentation of Phase 1 data for MRT-8102, a drug targeting people with elevated c…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease
The $50 million milestone payment is a substantial non-dilutive cash infusion for Monte Rosa Therapeutics, significantly strengthening its balance sheet and extending its cash runw…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.